AUCKLAND, New Zealand--(BUSINESS WIRE)--Ubiquitome’s ability to deliver fast test results for COVID-19 is attracting global inquires and top talent keen to get it to countries in desperate need.
Ubiquitome says, since the United Kingdom’s top COVID-19 research team revealed it was considering using Liberty 16 to test front line medical staff, international scientists have realised waiting more than an hour for test results is not necessary.
The Liberty 16 is a handheld, battery-powered, real-time polymerase chain reaction (real-time PCR) device that can fast test and relay sample data via an iPhone app - all potentially within 40 minutes.
Called Liberty 16 because it can run 16 tests at the same time, it is a miniature DNA photocopier. It can amplify specific target DNA sequences to show the presence of any DNA of interest, whether that be human, animal, or wider environmental pathogens.
Dr Pickering says Ubiquitome has secured the services of Dr Susan J. Turner, a microbiologist with 30 years of experience across commercial, academic and government sectors. She will take the lead in explaining to governments and the scientific community how Liberty 16 works, the result of trials in the UK and Germany and the benefits of fast tracking it into the battle against COVID-19.
“The fight against COVID-19 is rightly being led globally by scientists,” Dr Pickering says. “Dr Turner has the expertise to explain quickly how Ubiquitome’s Liberty 16 can help in the frontline battle.”
Dr Turner spent five years in the United States as senior vice-president R&D at Bio Consortia. Another New Zealand-founded biotech, Bio Consortia moved to California after investment by Khosla Ventures and Otter Capital to join Khosla’s stable of “black swan” technology companies. Dr Turner led the establishment of the US R&D operation, which now operates with 35 scientists developing microbial products for crop improvement.
Prior to Bio Consortia, Dr Turner founded the microbial eco-genomics research group and centre for microbial innovation at the University of Auckland. She has also had early-career experience in public health.
Dr Pickering, a Harvard MBA graduate, has held executive roles with real time PCR market leader Life Technologies/Thermo Fisher.
Dr Paul Pickering
Tel: +64 27 9654812
Coronavirus - responding to a growing threat with dynamically deployable, early mobile molecular detection
The coronavirus outbreak is showing signs of being the long feared outbreak that finally outruns the static testing model which was already creaking at the seams with previous outbreaks such as H1N1 and SARS.
The military has long understood that with a fast-moving enemy, a rapid, dynamic deployment capability is key. Coronavirus is exactly that kind of enemy, moving at remarkable speed, largely uninhibited by our existing static deployments, throughout Asia, through the Middle East and now into Europe.
In response to the coronavirus outbreak today, we are announcing that we are reorienting our business to prioritize support for groups seeking the kind of dynamic, mobile coronavirus detection capabilities unique to the Liberty16. As an open mobile real time PCR system benchmarked against the gold standard systems, it is rapidly configured to the best in class, whether that be fast and efficient mastermixes, high specificity primer/probe design or simple-to-use sample preparation.
We’ve already successfully run coronavirus real time PCR assays on the Liberty16. We are now prioritizing groups around the world working to develop dynamically deployable mobile coronavirus solutions with preferred pricing and delivery. Right now that’s what we think the world needs.
In 2015, Holly Bowers was a post-doctoral fellow with the Monterey Bay Aquarium Research Institute (MBARI) and was a finalist in the Freedom For You grants program. Her prize was a Freedom 4 device, which allowed Holly to perform real-time analysis in the field for different algal bloom species.
Holly has been working in the field of harmful algae for over two decades. Her research career started in molecular gene therapy, then switched to harmful algae. She has a doctorate in the field of aquatic ecology and is an active member of the Monterey Bay (California) research community.
As a direct result of the success Holly and her colleagues experienced with the Freedom 4, they were asked to trial the upcoming Liberty16, Ubiquitome’s latest major advance in commercial qPCR systems.
The processes, testing and impact of the Freedom 4 and Liberty16 on Holly’s research has been outlined in a new case study. Holly provides details of the challenges they were facing, such as the need to be able to test algal bloom species dockside. The ability to perform analysis on the spot has a direct impact on decision-making and resources.
The case study also outlines:
The capabilities of the Liberty16 device are also set to be outlined by Holly in an upcoming interactive webinar, Beyond the Lab: How to generate high quality qPCR data anywhere. The moderated session will be a great opportunity to share your experiences and challenges with testing outside the lab, as well as any innovations or new technologies you've developed.
Holly will also be focusing on the ability of the Liberty16 to vastly improve the efficiency of harmful algal bloom (HAB) species detection. Enabling rapid and specific analyses from shore-side to ship deployments.
The webinar will be presented on 10 October at 1:00PM Pacific Standard Time. Register now to make sure you don't miss out on Holly's valuable insights into the advancement of early detection of HAB species using a portable qPCR machine.
AUCKLAND, New Zealand, Aug. 29, 2019 /PRNewswire/ -- Ubiquitome Limited, a developer of handheld, cloud connected genetic analysis devices, announced today that Richard Creager, has joined its Board of Directors. Ubiquitome's Liberty16 extends the company's leadership in commercially available handheld, mobile devices to offer gold standard real-time PCR performance wherever it is needed.
Richard Creager commented, "I am honored to serve on the Ubiquitome Limited Board of Directors and helping Ubiquitome transform life science customers' access to genomic information."
Dr. Creager most recently served as Senior Vice President of Beckman Coulter, Inc. with responsibility for Molecular Diagnostics. He led the introduction of Veris, one of the first sample-to-answer Molecular Diagnostic systems. Richard also was the company's Chief Scientific Officer with key responsibilities to develop the technology and menu strategies for the company's immunoassay and molecular diagnostic businesses. Richard is currently CTO of liquid biopsy company, nRichDX. He also serves on the Board of Directors of Onramp Bioinformatics, a genomics analysis platform company.
Richard S. Creager received his PhD in Microbiology from the University of Pittsburgh School of Medicine.
Paul Pickering, Ubiquitome CEO said, "Richard has a wealth of experience in developing successful products, systems and companies in the clinical diagnostics market. We are delighted to welcome his expertise to the Ubiquitome board as we seek to realize the potential of our mobile technologies for the benefit of patients around the world."
Fellow board member, Evangeline Gonzalez further remarked, "Richard Creager's experience in clinical product development is very important as Ubiquitome moves ever closer to launching applied clinical applications. We are excited to have him come aboard."
Ubiquitome is a global leader in mobile genetic analysis devices offering gold standard real-time PCR performance wherever it is needed. The company is seeking to revolutionize genetic analysis by creating access to genomic information whenever and wherever it is needed.
Ubiquitome to participate at Bio International Convention 2019
Auckland, NZ. 31 May 2019.
New Zealand-based developer Ubiquitome will be exhibiting at the 2019 BIO International Convention in Philadelphia from 3 – 6 June. This event attracts 16,000+ attendees from over 7,000 businesses worldwide, including the leading biotech and pharma companies.
The Convention celebrates globally important innovations in biotech that start with ‘one’: one meeting, one theory, one trial, one breakthrough.
Ubiquitome will be showcasing its breakthrough 'Personal' Genomics Device, the Liberty16. Building on the mobile design philosophy of the company’s ground-breaking Freedom4, the Liberty16 brings unprecedented affordability and flexibility to genomic testing.
The Liberty16 comes with built-in lithium ion batteries for two to three hours of mobile running time, as well as Bluetooth paired with an iPhone app, meaning samples can be run and tested in the field.
An open platform with gold standard performance, the Liberty16 is compatible with industry standard consumables and chemistries such as Taqman® and SYBR.
Where: Pennsylvania Convention Center, Philadelphia, PA
When: 3 - 6 June, 2019
Ubiquitome: Booth #4014
To schedule a time to view the Liberty16 at the BIO Convention and find out more about how you can run your assay whenever and wherever it is needed, please contact:
Dr Paul Pickering
President and CEO, Ubiquitome Limited
+1 650 730 4958